Anuh Pharma Limited

rs,

Date: 17th November, 2025 To, The Manager (Listing) BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai - 400 001 BSE Scrip Code: 506260 To, Listing Compliance Department

21.14%

25 376.73 Cr 75.20 Cr 20.87 Cr 20.87 Cr H1 FY 2024 310.98 Cr 73.43 Cr 30.46 Cr 30.46 Cr Variance 21.14% 2.42% (31.47) (31.47) Key Reasons for EBITDA Decline: • Lower sales of certain high-margin produ

2.42%

73 Cr 75.20 Cr 20.87 Cr 20.87 Cr H1 FY 2024 310.98 Cr 73.43 Cr 30.46 Cr 30.46 Cr Variance 21.14% 2.42% (31.47) (31.47) Key Reasons for EBITDA Decline: • Lower sales of certain high-margin products co

46%

on Revenue Split (Rs. In Cr.) 371 302 196 139 174 162 Top 5 customers contribution 46% 36% 27% 32% 33% 32% Domestic Export Total H1 FY 26 H1 FY 25 H1 FY 26 Export Sales Domes

36%

evenue Split (Rs. In Cr.) 371 302 196 139 174 162 Top 5 customers contribution 46% 36% 27% 32% 33% 32% Domestic Export Total H1 FY 26 H1 FY 25 H1 FY 26 Export Sales Domestic S

27%

e Split (Rs. In Cr.) 371 302 196 139 174 162 Top 5 customers contribution 46% 36% 27% 32% 33% 32% Domestic Export Total H1 FY 26 H1 FY 25 H1 FY 26 Export Sales Domestic Sales

32%

it (Rs. In Cr.) 371 302 196 139 174 162 Top 5 customers contribution 46% 36% 27% 32% 33% 32% Domestic Export Total H1 FY 26 H1 FY 25 H1 FY 26 Export Sales Domestic Sales H1 F

33%

Rs. In Cr.) 371 302 196 139 174 162 Top 5 customers contribution 46% 36% 27% 32% 33% 32% Domestic Export Total H1 FY 26 H1 FY 25 H1 FY 26 Export Sales Domestic Sales H1 FY 25

3%

25 Total Sales GEOGRAPHICAL EXPORT SALES H1 FY26 GEOGRAPHICAL EXPORT SALES H1 FY25 LATIN AMERICA 3% EUROPE 30% ASIA 30% AFRICA 33% NORTH AMERICA 4% LATIN AMERICA 4% EUROPE 14% ASIA 44% AFRIC

30%

les GEOGRAPHICAL EXPORT SALES H1 FY26 GEOGRAPHICAL EXPORT SALES H1 FY25 LATIN AMERICA 3% EUROPE 30% ASIA 30% AFRICA 33% NORTH AMERICA 4% LATIN AMERICA 4% EUROPE 14% ASIA 44% AFRICA 31% ROW 7

4%

OGRAPHICAL EXPORT SALES H1 FY25 LATIN AMERICA 3% EUROPE 30% ASIA 30% AFRICA 33% NORTH AMERICA 4% LATIN AMERICA 4% EUROPE 14% ASIA 44% AFRICA 31% ROW 7% 8 Product mix revenue contribution 1

14%

25 LATIN AMERICA 3% EUROPE 30% ASIA 30% AFRICA 33% NORTH AMERICA 4% LATIN AMERICA 4% EUROPE 14% ASIA 44% AFRICA 31% ROW 7% 8 Product mix revenue contribution 119 100 H1 FY25 H1 FY26 (I

“5 Message from Joint MD to see a clear revival We expect in margins in H2 as operational efficiencies improve and high-margin products regain momentum.”

“We also anticipate a meaningful recovery in overall profitability as these factors converge in the second half.”

“• We remain confident that H2 will deliver stronger volume traction, improved margins, and a return to our planned growth trajectory, keeping us on course to achieve our full‐year estimates.”

“The expansion project with state of the art manufacturing facility targeted at regulated market is completed and commercial production from the said new facility started w.e.f.”

“Servicing Society for better tomorrow to Donated Chhatrapati Shikshan for Mandal of Building Toilet Block for about 3200 student of the School Service Funds to Churchgate for for challenged Sports Donated Lions Promoting specially children's to Indian Donated Foundation (Project Aashayein) education children Development for underprivileged the to 36 CSR ….”

“Servicing Society for better tomorrow Donated to Late Shri Manilal Kantilal Charitable sonawala providing Trust education and accommodation to the needy girls for Donated to Indian Development Foundation (Project Dignity) for providing menstrual hygiene kits and sanitary pads for the needy girl children's Donated to Greensole Foundation for providing recycled footwear's and masks for the needy children's 37 Thank You For specific queries please feel free to contact; Mr.”

Financial performance

1

Key Reasons for EBITDA Decline

1

Strategic initiatives

1

Market leadership

1

Financial performance

Particulars Revenue Gross margin EBIDTA PBT H1 FY 2025 376.73 Cr 75.20 Cr 20.87 Cr 20.87 Cr H1 FY 2024 310.98 Cr 73.43 Cr 30.46 Cr 30.46 Cr Variance 21.14% 2.42% (31.47) (31.47)

Key Reasons for EBITDA Decline

• Lower sales of certain high-margin products compared to the previous year resulted in reduced contribution, with expected recovery in the second half. • Non-recurring maintenance expenses impacted profitability during the period. • Adverse currency movements led to unrealised and realised losses affecting margins. 5 Message from Joint MD to see a clear revival We expect in margins in H2 as operational efficiencies improve and high-margin products regain momentum. With better capacity utilisation, stabilising input costs, and stronger customer offtake, we remain confident of meeting our budgeted revenue for the year. We also anticipate a meaningful recovery in overall profitability as these factors converge in the second half. key operational updates: • Added a new intermediate block, taking us to 2 intermediate blocks and 9 API blocks, with total reactor capacity now at 240 KL. • • Increased effluent treatment capacity from 100 KL/day to 150 KL/day to support higher production volume

Strategic initiatives

• Focused push in Matured Markets supported by the recent appointment of a dedicated CMO to accelerate growth and customer engagement. R&D efforts are progressing well with a focused pipeline in diabetic care, anticoagulant therapies, and next‐generation anti‐malarials. We are also actively advancing select CDMO opportunities to strengthen long‐term innovation and strategic partnerships. • We remain confident that H2 will deliver stronger volume traction, improved margins, and a return to our planned growth trajectory, keeping us on course to achieve our full‐year estimates. We sincerely thank our investors, partners, and employees for their continued trust and support. Thank you. Ritesh Shah (Joint MD) Vivek Shah (Joint MD) 6 Financial performance highlights (last 5 years) Total Revenue (INR in Cr.) EBITDA  (INR in Cr.) 443 492 537 659 671 55 52 57 87 70 20‐21 21‐22 22‐23 23‐24 24‐25 20‐21 21‐22 22‐23 23‐24 24‐25 PBT  (INR in Cr.) 39 28 39 31 47 36 PAT  (INR in Cr.) 78 60 61 47 20‐21

Market leadership

Erythromycin salts Pyrazinamide Sulfadoxine Ambroxol HCL Gliclazide Clobetasol Propionate Betamethasone Dipropionate Competitive Advantage • Regulatory approvals • Environmental health and Safety Compliance (Audited an approved by Multinational companies). • Well diversified sourcing with backward integration in key products. • Surplus capacity available • Financially strong • Strong R&D capabilities 17 Product List Macrolides Higher Macrloides 1. Erythromycin 11,12 Carbonate 1. Azithromycin 2. Erythromycin Base Anti TB 3. Erythromycin Estolate 1. Pyrazinamide 4. Erythromycin Propionate 2. Isoniazid 5. Erythromycin Ethyl Succinate Anti Bacterial Anti Asthamatics 1. Acebrophylline Anti Diabetic 1. Gliclazide 2. Vildagliptin 3. Dapagliflozin 6. Erythromycin Phosphate 1. Chloramphenicol Antibiotic 7. Erythromycin Stearate 2. Chloramphenicol Palmitate 1. Sulfadimethoxine Expectorant 1.Ambroxol HCL 2.Acefylline Piperazine Quinolones 1.Moxifloxacin Anti Malarial 1. Sulfadoxine 2. Pyrimethami